Depression in Patients with Parkinson’s Disease

Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443–54 Herlofson Karlsen K, Larsen JP, Tandberg E, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 66: 431–5 Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson’s disease? Aretrospective case series. Mov Disord 1999; 14: 155–93 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 Starkstein SE, Preziosi TJ, Bolduc PL, et al. Depression in Parkinson’s disease. J Nerv Ment Dis 1990; 178: 27–31 Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71 Dahlstrom WG. An MMPI handbook: clinical interpretation. Vol. 1. Minneapolis (MN): University of Minnesota Press, 1992 Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–96 Montgomery SM. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol 1979; 3: 429–33 Yesavage JA, Brink RL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res 1982-83; 17: 37–49 Goldberg P. The detection of psychiatric illness by questionnaire. London: Oxford University Press, 1972 (Maudsley Monograph; 21) Goldberg D. Manual of the General Health Questionnaire. Windsor: NFER-Nelson, 1978 Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 1999; 19: 329–35 Danielczyk W, Streifler M, Konradi C, et al. Platelet MAO-B activity and the psychopathology of Parkinson’s disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand 1988; 78: 730–6 Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999; 46: 217–23 Masterman D, DeSalles A, Baloh RW, et al. Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson’s disease. Arch Neurol 1998; 55: 1201–8 Pilo L, Ring H, Quinn N, et al. Depression in multiple system atrophy and in idiopathic Parkinson’s disease: a pilot comparative study. Biol Psychiatry 1996; 39: 803–7 Levin BE, Llabre MM, Weiner WJ. Parkinson’s disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988; 51: 1401–4 Hantz P, Caradoc-Davies G, Caradoc-Davies T, et al. Depression in Parkinson’s disease. Am J Psychiatry 1994; 151: 1010–4 Doonief G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992; 49: 305–7 Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381–9 Mayeux R, Stern Y, Rosen J, et al. Depression, intellectual impairment, and Parkinson’s disease. Neurology 1981; 31: 645–50 Santamaria J, Tolosa E, Valles A. Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–3 Huber SJ, Friedenberg DL, Paulson GW, et al. The pattern of depressive symptoms varies with progression of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53: 275–8 Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 1996; 53: 175–9 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980 Tandberg E, Larsen JP, Aarsland D, et al. Risk factors for depression in Parkinson’s disease. Arch Neurol 1997; 54: 625–30 Brown RG, MacCarthy B, Gotham AM, et al. Depression and disability in Parkinson’s disease: a follow-up study of 132 cases. Psychol Med 1988; 18: 49–55 Starkstein SE, Berthier ML, Bolduc PL. Depression in patients with early versus late onset of Parkinson’s disease. Neurology 1989; 39: 1441–5 Kostic VS, Filipovic SR, Lecic D, et al. Effect of age on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 1265–7 Hofman A, Colette HJ, Bartels AI. Incidence and risk factors of Parkinson’s disease in the Netherlands. Neuroepidemiology 1989; 8: 296–9 Cote L. Depression: impact and management by the patient and family. Neurology 1999; 7 Suppl. 3: 7–9 Gonera EG, van’t Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997; 12(6): 871–6 Miyoshy K, Ueki A, Nagano O. Management of psychiatric symptoms of Parkinson’s disease. Eur Neurology 1996; 36: 49–54 Ellgring H, Seiler S, Nagel U, et al. Psychosocial problems of Parkinson patients: approaches to assessment and treatment. Adv Neurol 1990; 53: 349–53 Taylor AT, Saint-Cyr JA, Lang AE, et al. Parkinson’s disease and depression: acritical re-evaluation. Brain 1986; 109:279–92 Haltenhof H, Schroter C. Depression beim Parkinson-Syndrom: eine literatubersicht. Fortschr Neurol Psychiatr 1994; 62:94–101 Schiffer RB, Kurlan R, Rubin A, et al. Evidence for atypical depression in Parkinson’s disease. Am JPsychiatry 1988; 145: 1020–2 Jackson JA, Free GBM, Pike HV. The psychic manifestations in paralysis agitans. Arch Neurol Psychiatry 1923; 8: 680–4 Mindham RH. Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970; 33: 188–91 Brown GL, Wilson WP. Parkinsonism and depression. South Med Jour 1972; 65: 540–5 Mindham RHS, Marsden CD, Parkes JD. Psychiatric symptoms during L-dopa therapy for Parkinson’s disease and their relationship to physical disability. Psychol Med 1976; 6: 23–33 Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson’s disease. Dis Nerv Syst 1972; 9: 577–83 Ehmann TS, Beninger RJ, Gawel MJ, et al. Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990; 2: 3–9 Brown R, Jahanshahi M. Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61–84 Menza MA, Sage J, Marshall E, et al. Mood changes and ‘on-off’ phenomena in Parkinson’s disease. Mov Disord 1990; 5: 148–51 Cantello R, Gilli M, Riccio A, et al. Mood changes associated with ‘end-of-dose deterioration’ in Parkinson’s disease: a controlled study. J Neurol Neurosurg Psychiatry 1986; 49: 1182–90 Brown R, Marsden CD, Quinn N, et al. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1984; 47: 454–65 Warburton JS. Depressive symptoms in Parkinson patients referred for thalamotomy. J Neurol Neurosurg Psychiatry 1967; 30: 368–70 Singer E. The effect of treatment with levodopa on parkinson patients’ social functioning and outlook on life. J Chronic Dis 1974; 27: 581–94 Horn S. Some psychological factors in parkinsonism. J Neurol Neurosurg Psychiatry 1974; 37: 27–31 Robins AH. Depression in patients with parkinsonism. Br J Psychiatry 1976; 128: 141–5 Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122(5): 509–22 Cole JO, Jones RT, Klerman GL. Drug therapy. In: Spiegel EA, editor. Progress in neurology and psychiatry. New York (NY): Greene & Stratton, 1961; 16: 539–74 Cole JO, Klerman GL, Jones RT. Drug therapy. In: Spiegel EA, editor. Progress in neurology and psychiatry. New York (NY): Greene & Stratton, 1960; 15: 540 Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson’s disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971; 14: 427–55 Sjostrom R, Roos BE. 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis and the effect of probenecid treatment. Eur J Clin Pharmacol 1973; 6: 75–80 van Praag HM, Korf J, Schut T. Cerebral monoamines and depression. An investigation with the probenecid technique. Arch Gen Psychiatry 1973; 28: 827–31 Berger PA, Faull KF, Kilkowski J. CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry 1980; 137: 174–9 Vestergaard P, Soresen R, Hoppe E, et al. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand 1978; 58: 88–96 van Amsterdam JG, Opperhuizen A. Nitric oxide and biopterin in depression and stress. Psychiatry Res 1999; 85: 33–8 DiBella D, Catalano M, Cichon S. Association study of a null mutation in the dopamine D4 receptor gene in Italian patients with obsessive-compulsive disorder, bipolar mood disorder, and schizophrenia. Psychiatry Gen 1996; 6: 119–21 Gelenberg AJ, Gibson CH, Wojcik JD. Neurotransmitter precursors for the treatment of depression Psychopharmacol Bull 1982; 18:7–18 Mouret J, Lemoine P, Minuit MP, et al. L-Tyrosine cures, immediate and long-term, dopamine dependent depressions. Clinical and polygraphic studies. C R Acad Sci III 1988; 306: 93–8 van Praag HM, Korf J, Lakke JPWF, et al. Dopamine metabolism in depressions, psychoses, and Parkinson’s disease: the problem of the specificity of biological variables in behavior disorders. Psychol Med 1975; 5: 138–46 Mann JJ, Kapur S. A dopaminergic hypothesis of major depression. Clin Neuropharmacol 1995; 18: S57–S65 Feinberg M. Bupropion: new therapy for depression. Am Fam Physician 1990; 41: 1787–90 Miller WR, Rosillini RA, Seligman MER Learned helplessness and depression. In: Seligman MEP, Maser J, editors. Psychopathology: experimental models. San Francisco (CA): Freema, 1977: 104–30 Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992; 32: 1–17 Willner P. Dopamine and depression: a review of recent evidence. II. Theoretical approaches. Br Res Rev 1983; 6: 225–36 Depeu RA, Monroe SM. Learned helplessness in the perspective of the depressive disorders: conceptual and definitional issues. J Abnorm Psychol 178; 87: 3–20 Stevens JR, Livermore Jr A. Kindling of the mesolimbic dopamine system: animal model of psychosis. Neurology 1978; 28: 36–46 Wise RA. Catecholamine theories of reward: a critical review. Brain Res 1978; 152:215–47 Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988; 45: 497–501 Glowinski J, Tassin JP, Thierry AM. The mesocortico-prefrontal dopaminergic neurons. Trends Neurosci 1984; 7: 415–8 Simon H, Le Moal M, Calas A. Efferents and afferents of the ventral tegmental-A10 region studies after local injection of [3 H]-leucine and horseradish perioxidase. Brain Res 1979; 178: 17–40 Mayberg H, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 1990; 28: 57–64 Mayeux R. Depression in the patient with Parkinson’s disease. J Clin Psychiatry 1990; 51: 20–3 Mayeux R, Stern Y, Williams JBW, et al. Clinical and biochemical features of depression in Parkinson’s disease. Am J Psychiatry 1986; 143: 756–9 Lloyd KJ, Farley IJ, Deck JHN, et al. Serotonin and 5-hydroxyindoleacetic acid in discrete areas of brainstem of suicide victims and controls. Adv Biochem Psychopharmacol 1974; 11: 387–97 Kuhn W, Muller T, Gerlach M, et al. Depression in Parkinson’s disease: biogenic amines in CSF of ‘de novo’ patients. J Neural Transm 1996; 103(12): 1441–5 Robinson RG, Kubos KL, Starr LB, et al. Mood disorders in stroke patients: importance of location of lesion. Brain 1984; 107: 81–93 Starkstein SE, Robinson RG, Price TR. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain 1987; 110: 1045–59 Grafman J, Vance SC, Weingartner H, et al. The effects of lateralized frontal lesions on mood regulation. Brain 1986; 109: 1127–48 Mesulam MM. Frontal cortex behaviour. Ann Neurol 1986; 19: 320–5 Ring HA, Bench CJ, Trimble MR, et al. Depression in Parkinson’s disease. A position emission study. Br J Psychol 1994; 165: 333–9 Baxter LR, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psych 1989; 46: 243–50 Bench CJ, Friston KJ, Brown RG, et al. The anatomy of melancholia-focal abnormalities of cerebral blood flow in major depression and the cognitive impairment of depression. Psychol Med 1992; 22: 607–15 Doherty S, Barber D, Hunt E, et al. Clinical correlates of resting state cerebral blood flow abnormalities in depressed patients with Parkinson’s disease. A 99m-Tc-HMPAO SPECT study [abstract]. Neurology 1997; 48: A352 Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340: 1476–80 Becker T, Becker G, Seufert J, et al. Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry 1997; 63: 590–6 Becker G, Struck U, Bogdagn U, et al. Echogenicity of the brainstem raphe in patients with major depression. Psychiatry Res Neuroimaging 1994; 55: 75–84 Becker G, Becker T, Struch M, et al. Reduced echogenicity of brainstem raphe specific to unipoloar depression: a transcranial color-coded real-time sonography study. Biol Psychiatry 1995; 38: 180–4 Ellgring H, Seiler S, Perleth B, et al. Psychosocial aspects of Parkinson’s disease. Neurology 1993; 43 Suppl. 6: 41–4 Strang RR. Imipramine in treatment of parkinsonism: a double-blind placebo study. Br Med J 1965; 2: 33–4 Laitinen L. Desipramine in treatment of Parkinson’s disease: a placebo-controlled study. Acta Neurol Scand 1969; 45: 109–13 Denmark JC, David JDP, McComb SG. Imipramine hydrocholride (tofranil) in parkinsonism. A preliminary report. Br J Clin Prac 1961; 15:523–4 Andersen J, Aabro E, Gulman N, et al. Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol Scand 1980; 62: 210–9 Randrup A, Munkvad I, Fog J, et al. Mania, depression, and brain dopamine. Curr Dev Psychopharmacol 1975; 2: 206–48 Ghosh PK, Hrdina PD. Effects of tricyclic antidepressants on the content and metabolism of dopamine in the rat striatum. Can J Physiol Pharmacol 1976; 55: 383–8 Halaris AE, Belendiuk KT, Freedman DX. Antidepressant drugs affect dopamine uptake. Biochem Pharmacol 1975; 24: 1896–989 Alpers HS, Himwich HE. Effects of repeated daily injections of imipramine on brain levels of serotonin, 5-hydroxyindoleacetic acid, norepinephrine and dopamine [abstract]. Fed Proc 1971; 30: 672 Richard IH, Kurlan R, and the Parkinson Study Group. A survey of antidepressant drug use in Parkinson’s disease. Neurology 1997; 49: 1168–70 Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997; 12: 756–9 Meara J, Hobson P. Sertraline for the treatment of depression in Parkinson’s disease [letter; comment]. Mov Disord 1998; 13(3): 622 Wittgens W, Donath O, Trenckmann U. Treatment of depressive syndromes in Parkinson’s disease with paroxetine [abstract]. Mov Disord 1997; 12: 128 Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology 1984; 34: 1092–4 Tate JL. Extrapyramidal symptoms in a patient taking haldoperidol and fluoxetine. Am J Psychiatry 1989: 146; 399-400 Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology 1994; 44(12): 2406 Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–3 Montastruc JL, Fabre N, Blin O. Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 1995; 10: 355–6 Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 1992; 53: 278–82 Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705–13 Feigher JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–50 Suchowersky Q, DeVries J. Possible interactions between deprenyl and prozac. Can J Neurol Sci 1990; 17: 352–3 Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341 (8844): 555 Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45: 219–23 Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997; 60: 419–33 Waters CH. Fluoxetine and selegiline. Can J Neurol Sci 1994; 21: 259–61 Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994; 28: 405–6 Richard I, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology 1997; 48(4): 1070–7 Rudorfer MV. Monoamine oxidase inhibitors: reversible and irreversible. Psychopharm Bul 1992; 28: 45–57 Knoll J, Ecseri Z, Kelemen K, et al. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965; 155: 154–64 Sunderland T, Cohen R, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patient. Arch Gen Psychiatry 1994; 51: 607–15 Marek GJ, Seiden LS. Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior. Psychopharmacology 1988; 96: 153–60 Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (()-deprenyl. Arch Gen Psychol 1989; 46: 45–50 Mendis N, Pare CMB, Sandier M, et al. Is the failure of l-deprenyl, a selective MAO-B inhibitor, to alleviate depression related to freedom from cheese effect? Psychopharmacology 1981; 73: 87–90 McGrath PJ, Stewart JW, Quitkin FM. A possible l-deprenyl induced hypertensive reaction. J Clin Psychopharm 1989; 9: 310–1 Sunderland T, Mueller EA, Cohen RM, et al. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 1985; 86: 432–7 Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists is an animal model of depression. Biol Psychiatry 1992; 31: 937–46 Theohar C, Fischer-Cornelssen K, Akesson HO, et al. Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 1981; 30: 830–41 Post RM, Gerner RH, Carman JS, et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35: 609–15 Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993; 29: 207–11 Grander G, Wetzel H, Hammes E, et al. Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharamcology (Berl) 1993; 111: 123–6 Kasper S, Barnas C, Heiden A, et al. Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy. Eur Neuropsychopharmacol 1997; 7: 65–70 Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression [letter]. Am J Psychiatry 1999; 156(5): 798